Meanwhile, patients with BLCA in the high-ANLN expression group showed poor CSS, progression-free survival (PFS) and RFS, compared with the low-ANLN expression group (Zeng et al., 2017). This evidence concerns the gene ANLN and bladder transitional cell carcinoma.